Qualigen Therapeutics (QLGN -3.6%) has signed a worldwide license agreement with the University of Louisville for “RAS-F” family of RAS oncogene protein-protein interaction inhibitor small molecule drug candidates.
The company will evaluate these compounds in order to identify a lead drug candidate for further development against one or more cancers.
UofL royalties will receive low-to-mid-single-digit percentages on net sales of RAS protein-protein licensed products.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.